Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NANBH
MCID: HPT001
MIFTS: 62

Hepatitis C (NANBH)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hepatitis C

About this section

MalaCards integrated aliases for Hepatitis C:

Name: Hepatitis C 12 74 54 42 43 15 37 71
Hepatitis C Infection 12 15
Hepatitis C, Chronic 71
Chronic Hepatitis C 12
Hepatitis Nona Nonb 12
Hepatitis C Chronic 54
Viral Hepatitis C 12
Nanbh 12

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Liver diseases Immune diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1883
ICD9CM 34 070.7
MeSH 43 D006526
NCIt 49 C3098
SNOMED-CT 67 50711007
ICD10 32 B19.20
UMLS 71 C0019196 C0524910
Sources

Summaries for Hepatitis C

About this section
MedlinePlus : 42 What is hepatitis C? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. Inflammation can damage organs. There are different types of hepatitis. One type, hepatitis C, is caused by the hepatitis C virus (HCV). Hepatitis C can range from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C can be acute or chronic: Acute hepatitis C is a short-term infection. The symptoms can last up to 6 months. Sometimes your body is able to fight off the infection and the virus goes away. But for most people, an acute infection leads to chronic infection. Chronic hepatitis C is a long-lasting infection. If it is not treated, it can last for a lifetime and cause serious health problems, including liver damage, cirrhosis (scarring of the liver), liver cancer, and even death. How is hepatitis C spread? Hepatitis C spreads through contact with the blood of someone who has HCV. This contact may be through Sharing drug needles or other drug materials with someone who has HCV. In the United States, this is the most common way that people get hepatitis C. Getting an accidental stick with a needle that was used on someone who has HCV. This can happen in health care settings. Being tattooed or pierced with tools or inks that were not sterilized after being used on someone who has HCV Having contact with the blood or open sores of someone who has HCV Sharing personal care items that may have come in contact with another person's blood, such as razors or toothbrushes Being born to a mother with HCV Having unprotected sex with someone who has HCV Before 1992, hepatitis C was also commonly spread through blood transfusions and organ transplants. Since then, there has been routine testing of the U.S. blood supply for HCV. It is now very rare for someone to get HCV this way. Who is at risk for hepatitis C? You are more likely to get hepatitis C if you Have injected drugs Had a blood transfusion or organ transplant before July 1992 Have hemophilia and received clotting factor before 1987 Have been on kidney dialysis Were born between 1945 and 1965 Have abnormal liver tests or liver disease Have been in contact with blood or infected needles at work Have had tattoos or body piercings Have worked or lived in a prison Were born to a mother with hepatitis C Have HIV/AIDS Have had more than one sex partner in the last 6 months Have had a sexually transmitted disease Are a man who has had sex with men If you are at high risk for hepatitis C, your health care provider will likely recommend that you get tested for it. What are the symptoms of hepatitis C? Most people with hepatitis C have no symptoms. Some people with acute hepatitis C do have symptoms within 1 to 3 months after they are exposed to the virus. These symptoms may include Dark yellow urine Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Pain in your abdomen Jaundice (yellowish eyes and skin) If you have chronic hepatitis C, you probably will not have symptoms until it causes complications. This can happen decades after you were infected. For this reason, hepatitis C screening is important, even if you have no symptoms. What other problems can hepatitis C cause? Without treatment, hepatitis C may lead to cirrhosis, liver failure, and liver cancer. Early diagnosis and treatment of hepatitis C can prevent these complications. How is hepatitis C diagnosed? Health care providers diagnose hepatitis C based on your medical history, a physical exam, and blood tests. If you do have hepatitis C, you may need additional tests to check for liver damage. These tests may include other blood tests, an ultrasound of the liver, and a liver biopsy. What are the treatments for hepatitis C? Treatment for hepatitis C is with antiviral medicines. They can cure the disease in most cases. If you have acute hepatitis C, your health care provider may wait to see if your infection becomes chronic before starting treatment. If your hepatitis C causes cirrhosis, you should see a doctor who specializes in liver diseases. Treatments for health problems related to cirrhosis include medicines, surgery, and other medical procedures. If your hepatitis C leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis C be prevented? There is no vaccine for hepatitis C. But you can help protect yourself from hepatitis C infection by Not sharing drug needles or other drug materials Wearing gloves if you have to touch another person's blood or open sores Making sure your tattoo artist or body piercer uses sterile tools and unopened ink Not sharing personal items such toothbrushes, razors, or nail clippers Using a condom when you have sex NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis C, also known as hepatitis c infection, is related to hepatitis c virus and cryoglobulinemia, familial mixed, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis C is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Zinc and Acarbose have been mentioned in the context of this disorder. Affiliated tissues include Blood, liver and testes.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis C virus, which is transmitted by blood from an infected person enters the body of an uninfected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 74 Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the... more...

Sources

Related Diseases for Hepatitis C

About this section

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1305)
# Related Disease Score Top Affiliating Genes
1 hepatitis c virus 34.5 SCARB1 KRT18 IRF3 IFNG GPT EIF2AK2
2 cryoglobulinemia, familial mixed 33.5 IFNA2 IFNA1
3 liver disease 33.1 MIR122 KRT18 IFNA2 IFNA1 GPT
4 viral hepatitis 32.9 MX1 MIR122 KRT18 IFNG IFNA2 IFNA1
5 hepatitis 32.8 SCARB1 KRT18 IRF3 IFNG IFNA2 IFNA1
6 cryoglobulinemia 32.4 IFNG IFNA2 IFNA1 GPT CD81
7 hepatitis a 32.1 IFNG IFNA2 IFNA1 GPT
8 liver cirrhosis 31.9 MIR122 KRT18 IFNA1 HOTAIR GPT
9 exanthem 31.9 IFNG IFNA1 GPT
10 autoimmune hepatitis 31.9 KRT18 IFNA1 GPT
11 neutropenia 31.8 IFNG IFNA2 IFNA1 GPT
12 hepatitis b 31.8 MX1 IFNG IFNB1 IFNA2 IFNA1 GPT
13 immune deficiency disease 31.7 IFNG IFNB1 IFNA1 GPT EIF2AK2 CLEC4M
14 hepatitis d 31.6 IFNA2 IFNA1 GPT EIF2AK2
15 human immunodeficiency virus infectious disease 31.6 MX1 IFNG IFNA1 CLEC4M
16 thrombocytopenia 31.6 IFNG IFNB1 IFNA2 IFNA1 GPT
17 vaccinia 31.5 IRF3 IFNB1 IFNA1 EIF2AK2
18 non-alcoholic steatohepatitis 31.3 MIR122 KRT18 GPT
19 primary biliary cirrhosis 31.3 MIR122 KRT18 IFNG IFNA1 GPT
20 diarrhea 31.2 IRF3 IFNG IFNB1 IFNA2 IFNA1 GPT
21 west nile virus 31.2 IRF3 IFNA1 DDX58 CLEC4M
22 japanese encephalitis 31.1 IFNB1 IFNA1 CLEC4M
23 bacterial infectious disease 31.0 MX1 IRF3 IFNG IFNB1
24 hepatitis e 31.0 MIR122 IFNG IFNB1 GPT DDX58
25 stomatitis 30.9 MX1 IFNG IFNB1 IFNA2 IFNA1 EIF2AK2
26 herpes simplex 30.9 IRF3 IFNB1 IFNA1 EIF2AK2 DDX58
27 oral erosive lichen 30.9 IFNB1 IFNA1
28 herpes zoster 30.8 IFNG IFNA2 IFNA1
29 kaposi sarcoma 30.7 IRF3 IFNB1 IFNA2 IFNA1
30 tick-borne encephalitis 30.7 IFNB1 IFNA1 DDX58
31 cutaneous lupus erythematosus 30.7 MX1 IFNG IFNA1
32 rabies 30.7 MX1 IRF3 IFNA1 DDX58
33 chickenpox 30.6 MIR122 IFNG IFNB1 IFNA1
34 lymphocytic choriomeningitis 30.6 IRF3 DDX58 DDX3X
35 viral infectious disease 30.6 MX1 MIR122 IRF3 IFNG IFNB1 IFNA2
36 rubella 30.6 IFNG IFNB1 GPT DDX58
37 measles 30.5 IRF3 IFNG IFNB1 IFNA1 EIF2AK2 DDX58
38 systemic lupus erythematosus 30.5 MX1 IRF3 IFNG IFNB1 IFNA2 IFNA1
39 gastroenteritis 30.5 IFNG IFNA2 IFNA1
40 encephalitis 30.5 MX1 IRF3 IFNB1 IFNA1 DDX58 DDX3X
41 biliary atresia 30.5 MX1 IFNG GPT
42 severe acute respiratory syndrome 30.5 MX1 IRF3 IFNG IFNB1 IFNA1 GPT
43 pneumonia 30.4 IFNG IFNB1 IFNA1 GPT
44 venezuelan equine encephalitis 30.4 IFNG IFNB1 IFNA1 DDX3X
45 hairy cell leukemia 30.4 IFNB1 IFNA2 IFNA1
46 mouth disease 30.4 MX1 IRF3 IFNG IFNA1 DDX58
47 influenza 30.3 MX1 IRF3 IFNG IFNB1 IFNA1 EIF2AK2
48 viral encephalitis 30.3 MX1 IFNB1 IFNA1 DDX58
49 newcastle disease 30.3 IRF3 IFNB1 IFNA1 EIF2AK2 DDX58
50 lassa fever 30.2 IRF3 IFNA1 DDX58

Graphical network of the top 20 diseases related to Hepatitis C:



Diseases related to Hepatitis C
Sources

Symptoms & Phenotypes for Hepatitis C

About this section

Symptoms:

12
  • • vomiting
  • • fatigue
  • • fever
  • • abdominal pain
  • • jaundice
  • • nausea
  • • loss of appetite
  • • joint pain
  • • clay-colored bowel movements
Sources

Drugs & Therapeutics for Hepatitis C

About this section

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 582)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
3
Insulin glulisine Approved Phase 4 207748-29-6
4
Insulin glargine Approved Phase 4 160337-95-1
5
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
6
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
7
Losartan Approved Phase 4 114798-26-4 3961
8
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
9
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
13
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
14
Citalopram Approved Phase 4 59729-33-8 2771
15
Colchicine Approved Phase 4 64-86-8 2833 6167
16
Infliximab Approved Phase 4 170277-31-3
17
Promethazine Approved, Investigational Phase 4 60-87-7 4927
18
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
19
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
20
Didanosine Approved Phase 4 69655-05-6 50599
21
Zidovudine Approved Phase 4 30516-87-1 35370
22
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
23
Fosamprenavir Approved Phase 4 226700-79-4 131536
24
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
25
Nelfinavir Approved Phase 4 159989-64-7 64143
26
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
27
Baclofen Approved Phase 4 1134-47-0 2284
28
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
29
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
30
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
31 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
32
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
33
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
34
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
35
Insulin aspart Approved Phase 4 116094-23-6 16132418
36
Insulin detemir Approved Phase 4 169148-63-4 5311023
37
Cobicistat Approved Phase 4 1004316-88-4
38
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
39
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
40
Lactulose Approved Phase 4 4618-18-2 11333
41
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
42
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
43
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
44
Azathioprine Approved Phase 4 446-86-6 2265
45
Topiramate Approved Phase 4 97240-79-4 5284627
46
Lenvatinib Approved, Investigational Phase 4 417716-92-8
47
Methadone Approved Phase 4 76-99-3 4095
48
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
49
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
50
tannic acid Approved Phase 4 1401-55-4

Interventional clinical trials:

(show top 50) (show all 2710)
# Name Status NCT ID Phase Drugs
1 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
2 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
3 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
4 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
5 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
6 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
7 An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Unknown status NCT02950870 Phase 4 Ombitasvir-Paritaprevir-Ritonavir;Dasabuvir;Ribavirin
8 Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
9 A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes Unknown status NCT02461745 Phase 4 ombitasvir, paritaprevir/r, dasabuvir + ribavirin;ombitasvir, paritaprevir/r, dasabuvir
10 Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs Unknown status NCT02609893 Phase 4
11 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
12 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
13 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
14 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
15 Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4 Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
16 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
17 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
18 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
19 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
20 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
21 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
22 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
23 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
24 A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Unknown status NCT03003338 Phase 4 OBV/PTV/r and DSV;Placebo to match OBV/PTV/r and DSV
25 Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02745132 Phase 4
26 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
27 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
28 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
29 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
30 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
31 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
32 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
33 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
34 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
35 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
36 The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial Unknown status NCT00841243 Phase 4
37 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
38 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
39 Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
40 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
41 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
42 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
43 Safety and Efficacy of Immunosuppression With Basiliximab, Delayed Dose Tacrolimus Plus Enteric Coated Mycophenolic Acid, Versus Standard Dose Tacrolimus, Enteric Coated Mycophenolic Acid Plus Corticosteroids in Patients Undergoing Orthotopic Liver Transplantation (OLT) Unknown status NCT02123108 Phase 4 Basiliximab
44 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
45 Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro) Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
46 Efficacy and Safety of Neutrino Therapy for Chronic HCV Genotype 1b Treatment-experienced Patients Completed NCT02480686 Phase 4 SOF+PEG+RBV
47 Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection Completed NCT02482077 Phase 4 SOF+RBV;SOF+DCV;LDV/SOF
48 Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study Completed NCT02220868 Phase 4 Sofosbuvir, Ribavirin, and Stribild
49 An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes With Patient Demographics and Disease Characteristics in Patients With Chronic Hepatitis C Completed NCT01675427 Phase 4
50 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma Completed NCT00630084 Phase 4 pegylated interferon alpha 2a and plus ribavirin;pegylated interferon alpha 2a and plus ribavirin

Search NIH Clinical Center for Hepatitis C

Inferred drug relations via UMLS 71 / NDF-RT 50 :


boceprevir
daclatasvir
dasabuvir
elbasvir
grazoprevir
Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor [EPC]
Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]
Hepatitis C Virus NS5A Inhibitor [EPC]
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
ledipasvir
ombitasvir
paritaprevir
PEGINTERFERON
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Ribavirin
simeprevir
sofosbuvir
telaprevir
velpatasvir

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis C cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis C:
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Embryonic/Adult Cultured Cells Related to Hepatitis C:
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151

Cochrane evidence based reviews: hepatitis c

Sources

Genetic Tests for Hepatitis C

About this section
Sources

Anatomical Context for Hepatitis C

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis C:

19
Liver

MalaCards organs/tissues related to Hepatitis C:

40
Liver, Testes, Kidney, T Cells, B Cells, Thyroid, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hepatitis C:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
Sources

Publications for Hepatitis C

About this section

Articles related to Hepatitis C:

(show top 50) (show all 32917)
# Title Authors PMID Year
1
Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents. 42 61
32384505 2020
2
Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. 46 61
19122656 2009
3
Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals. 42
32276399 2020
4
Factors influencing treatment outcome in hepatitis C virus minority patients at an inner-city hospital: A STROBE-complaint article. 42
32243366 2020
5
Relationship between serum concentrations of keratin-18 and apoptosis in chronic hepatitis C. 61 54
20374042 2010
6
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. 54 61
20235331 2010
7
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. 61 54
20169624 2010
8
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. 61 54
20186843 2010
9
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 61 54
19881359 2010
10
Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. 54 61
20222873 2010
11
Tissue and serum immune response in chronic hepatitis C with mild histological lesions. 54 61
20209325 2010
12
Serum cytokine profile in hepatitis C virus carriers presenting cryoglobulinaemia and non-organ-specific autoantibodies. 61 54
20005287 2010
13
Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy. 61 54
20203368 2010
14
Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. 61 54
19918044 2010
15
Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. 54 61
19944069 2010
16
Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. 61 54
19769973 2010
17
[Investigation of the relationship between hepatitis c virus (HCV) genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis c patients]. 61 54
20455406 2010
18
Retinol supplements antiviral action of interferon in patients with chronic hepatitis C: a prospective pilot study. 54 61
20104263 2010
19
Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. 54 61
20014458 2009
20
Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. 61 54
19776133 2009
21
Do statins reduce hepatitis C RNA titers during routine clinical use? 54 61
19859994 2009
22
Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. 61 54
19586676 2009
23
Interleukin-10 promoter polymorphisms in hepatitis C patients with and without Schistosoma mansoni co-infection. 54 61
19555400 2009
24
APRI as a predictor of early viral response in chronic hepatitis C patients. 61 54
19842223 2009
25
Prolonged psychosis associated with interferon therapy in a patient with hepatitis C: case study and literature review. 54 61
19855041 2009
26
[The association of genetic polymorphism of dendritic cell-specific ICAM-grabbing nonintegrin and hepatitis C infection]. 54 61
19785948 2009
27
Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. 61 54
19740312 2009
28
Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus. 61 54
19538950 2009
29
Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. 61 54
19628164 2009
30
Human VAP-C negatively regulates hepatitis C virus propagation. 61 54
19515777 2009
31
Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. 61 54
19302182 2009
32
Schistosoma mansoni coinfection could have a protective effect against mixed cryoglobulinaemia in hepatitis C patients. 61 54
19192170 2009
33
Antioxidant status and lipid peroxidation activity in evaluating hepatocellular damage in children. 54 61
20187535 2009
34
TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. 61 54
19475618 2009
35
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. 61 54
19489072 2009
36
Circulating levels of interferon-gamma in course of hepatitis C virus-related arthritis. 61 54
19450146 2009
37
Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha. 61 54
19238512 2009
38
Is {beta}-interferon a promising therapeutic option for the management of hepatitis C? 61 54
19329508 2009
39
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. 54 61
19200135 2009
40
Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. 61 54
19253371 2009
41
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry. 54 61
19476617 2009
42
Serum level of adiponectin correlated with gender and genotype in patients with chronic hepatitis C. 54 61
18773295 2009
43
Hepatitis C infection and apoptosis in hepatocellular carcinoma. 61 54
19806812 2009
44
Evolution of hepatitis C virus hypervariable region 1 in immunocompetent children born to HCV-infected mothers. 61 54
19228286 2009
45
[Clinical features of interstitial pneumonitis due to interferon alpha therapy for chronic hepatitis C]. 61 54
19403391 2009
46
Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. 61 54
19480854 2009
47
Clinical implications of alpha-fetoprotein in chronic hepatitis C. 61 54
19293036 2009
48
Serum autoantibodies against cytochrome P450 2E1 (CYP2E1) predict severity of necroinflammation of recurrent hepatitis C. 61 54
19191768 2009
49
Treatment of hepatitis C in liver transplant recipients. 54 61
19177439 2009
50
Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE gene. A case-control study. 61 54
19001803 2009
Sources

Variations for Hepatitis C

About this section
Sources

Expression for Hepatitis C

About this section
Search GEO for disease gene expression data for Hepatitis C.
Sources

Pathways for Hepatitis C

About this section

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 65
Show member pathways
 13.22 MX1 IRF3 IFNG IFNB1 IFNA2 IFNA1
2
PI3K-Akt signaling pathway 36
Show member pathways
 12.87 MX1 IRF3 IFNB1 IFNA2 IFNA1 EIF2AK2
3
Human cytomegalovirus infection 36
Show member pathways
 12.79 IRF3 IFNB1 IFNA2 IFNA1 EIF2AK2
4
Herpes simplex virus 1 infection 36
12.64 IRF3 IFNG IFNB1 IFNA2 IFNA1 EIF2AK2
5
Measles 36
Show member pathways
 12.62 MX1 IRF3 IFNG IFNB1 IFNA2 IFNA1
6
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways